Bispecifics and conditionally active mAbs top ASCO abstract stock moves
Also in BioCentury’s ASCO Report, an ADC disappointment from Daiichi and Merck, a PI3K inhibitor success from Roche, and more
Few abstracts released ahead of the American Society of Clinical Oncology (ASCO) conference led to major stock moves, but they preview plenty of interesting clinical data.
In addition to Merus N.V. (NASDAQ:MRUS), which gained 33% after the abstracts were released, Adagene Inc. (NASDAQ:ADAG) rose 12% on data suggesting a conditionally active formulation of an anti-CTLA-4 may help solve the therapeutic index problems of the class. ...
BCIQ Target Profiles
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)
Epidermal growth factor receptor (EGFR) (ErbB1) (HER1)
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Phosphoinositide 3-kinase (PI3K)
Phosphoinositide 3-kinase (PI3K) class 2 subunit alpha polypeptide (PI3KC2A)